Skip navigation
Home
Browse
Communities
& Collections
Browse Items by:
Issue Date
Author
Title
Advisor
Help
Sign on to:
My DSpace
Receive email
updates
Edit Profile
Adelaide Research & Scholarship
Adelaide Research & Scholarship
Search
Search:
All collections
Schools and Disciplines
School of Medicine
Medicine
Medicine publications
for
Current filters:
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Start a new search
Add filters:
Use filters to refine the search results.
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Results 21-30 of 171 (Search time: 0.003 seconds).
previous
1
2
3
4
5
6
...
18
next
Item hits:
Preview
Issue Date
Title
Author(s)
1998
Establishment of a reproducible model of chronic-phase chronic myeloid leukemia in NOD/SCID mice using blood-derived mononuclear or CD34+ cells
Lewis, I.
;
McDiarmid, L.
;
Samels, L.
;
To, L.
;
Hughes, T.
2010
Towards DNA-based monitoring of therapy in chronic myeloid leukemia
Morley, A.
;
Bartley, P.
;
Ross, D.
;
Latham, S.
;
Budgen, B.
;
Branford, S.
;
Hughes, T.
;
American Society of Hematology Meeting (52nd : 2010 : Florida, CA.)
2010
Contrasting response of patients with chronic myeloid leukaemia (CML) and the highly imatinib resistant L248V mutation that may be related to an increased propensity of some patients to form an associated deletion mutant with increased imatinib sensitivity
Prime, H.
;
Romeo, G.
;
Phillis, S.
;
Field, C.
;
Jamison, B.
;
Prime, J.
;
Parker, W.
;
Joske, D.
;
Hughes, T.
;
Branford, S.
;
Haematology Association of Australasia Annual Meeting (2010 : Auckland, New Zealand)
2007
Monitoring disease response
Hughes, T.
;
Branford, S.
;
Melo, J.
;
Goldman, J.
2010
Limiting the variability within a BCR-ABL quantitative PCR (RQ-PCR) assay is essential for optimal concordance of results between laboratories generating BCR-ABL values on an international reporting scale
Fletcher, L.
;
Prime, J.
;
Phillis, S.
;
Jamison, B.
;
Field, C.
;
Prime, H.
;
Sullivan, B.
;
Yeoman, A.
;
Georgievski, J.
;
Parker, W.
;
Slader, C.
;
Hughes, T.
;
Branford, S.
;
Haematology Association of Australasia Annual Meeting (2010 : Auckland, New Zealand)
2014
The adverse effect of high sokal risk for first line imatinib treated patients is overcome by a rapid rate of BCR-ABL decline measured as early as 1 month of treatment
Branford, S.
;
Yeung, D.
;
Ross, D.
;
Parker, W.
;
Braley, J.
;
Seymour, J.
;
Hughes, T.
;
56th ASH Annual Meeting (6 Dec 2014 - 9 Dec 2014 : San Francisco, California)
2006
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Druker, B.
;
Guilhot, F.
;
O'Brien, S.
;
Gathmann, I.
;
Kantarjian, H.
;
Gattermann, N.
;
Deininger, M.
;
Silver, R.
;
Goldman, J.
;
Stone, R.
;
Cervantes, F.
;
Hochhaus, A.
;
Powell, B.
;
Gabrilove, J.
;
Rousselot, P.
;
Reiffers, J.
;
Cornelissen, J.
;
Hughes, T.
;
Agis, H.
;
Fischer, T.
;
et al.
2000
Normal and leukemic engraftment in the nod/scid mouse model
Hughes, T.
;
White, D.
;
Bresatz, S.
;
Forte, M.
;
Lewis, I.
;
Lyons, A.
2017
Reduced CD62L expression on T cells and increased soluble CD62L levels predict molecular response to tyrosine kinase inhibitor therapy in early chronic-phase chronic myelogenous leukemia
Sopper, S.
;
Mustjoki, S.
;
White, D.
;
Hughes, T.
;
Valent, P.
;
Burchert, A.
;
Gjertsen, B.
;
Gastl, G.
;
Baldauf, M.
;
Trajanoski, Z.
;
Giles, F.
;
Hochhaus, A.
;
Ernst, T.
;
Schenk, T.
;
Janssen, J.
;
Ossenkoppele, G.
;
Porkka, K.
;
Wolf, D.
2013
PCR-mediated recombination can lead to artificial chimera formation, which may pose as BCR-ABL1 compound mutations
Parker, W.
;
Phillis, S.
;
Yeung, D.
;
Hughes, T.
;
Scott, H.
;
Branford, S.
;
55th American Society of Hematology Annual Meeting and Exhibition (7 Dec 2013 - 10 Dec 2013 : New Orleans, Louisiana)
Discover
Author
61
Branford, S.
53
White, D.
35
Hochhaus, A.
22
Kantarjian, H.
22
Radich, J.
22
Saglio, G.
20
Kim, D.
20
Yeung, D.
19
Ross, D.
17
Cortes, J.
.
next >
Subject
90
Humans
65
Pyrimidines
64
Leukemia, Myelogenous, Chronic, B...
55
Piperazines
54
Benzamides
52
Imatinib Mesylate
42
Antineoplastic Agents
40
Fusion Proteins, bcr-abl
38
Protein Kinase Inhibitors
31
Male
.
next >
Date issued
1
2020 - 2022
97
2010 - 2019
64
2000 - 2009
9
1995 - 1999